-
Cardiol To Test Oral Cannabidiol Formulation In Acute Myocarditis Patients
Tuesday, August 24, 2021 - 8:24am | 245Read More...The FDA has signed off Cardiol Therapeutics Inc's (NASDAQ: CRDL) Investigational New Drug (IND) application for CardiolRx. Cardiol will commence a Phase 2, multi-center, double-blind, randomized, placebo-controlled trial to assess the safety and tolerability of CardiolRx in...
-
ScPharmaceuticals Sees US Application Submission For Furoscix In Q3
Tuesday, February 23, 2021 - 12:03pm | 358Read More...ScPharmaceuticals Inc (NASDAQ: SCPH) announced that after the Type A meeting with the FDA, the agency does not require any modifications to the device, nor it asked the company to conduct additional clinical studies to demonstrate the safety and efficacy of Furoscix. In...
-
Amgen's Repatha Results Not Good Enough For The Street
Friday, March 17, 2017 - 9:42am | 432Read More...Shares of Amgen, Inc. (NASDAQ: AMGN) fell 7 percent after the biotechnology company released data from its therapy called Repatha, which is used to lower the risk of heart attacks, strokes and heart problems. Amgen reported Repatha reduces the risk of heart attacks, stokes and other heart-related...
-
Novartis Announces The Establishment Of FortiHFy, But What Is It?
Thursday, May 19, 2016 - 10:04am | 303Read More...Novartis AG (ADR) (NYSE: NVS) announced on Thursday the establishment of FortiHFy, short for Fortifying Heart Failure clinical evidence and patient quality of life. FortiHFy is an umbrella clinical program that consists of over 40 active or planned trials. The global clinical program will result in...
